{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T22:39:44Z","timestamp":1776292784257,"version":"3.50.1"},"reference-count":73,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Influenza vaccines are the most useful strategy for preventing influenza illness, especially in the setting of the COVID-19 pandemic. For the coming year (2021\/2022) all vaccines will be quadrivalent and contain two influenza A strains [(H1N1)pdm09-like and (H3N2)-like viruses] and two influenza B strains (Victoria lineage-like and Yamagata lineage-like viruses). However, the currently licensed have suboptimal efficacy due to the emergence of new strains and vaccine production limitations. In this review, we summarize the current recommendations as well as new advancements in influenza vaccinations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Recent advances have been aimed at moving away from egg-based vaccines and toward cell culture and recombinant vaccines. This removes egg adaptations that decrease vaccine efficacy, removes the reliance on egg availability and decreases the time necessary to manufacture vaccines. However, even more radical changes are needed if we are to reach the ultimate goal of a universal vaccine capable of providing long-lasting protection against all or at least most influenza strains. We discuss various strategies, including using more stable influenza antigens such as the hemagglutinin stalk and internal proteins as well as new adjuvants, new vaccine formulations, and DNA\/RNA-based vaccines that are currently being developed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The currently available vaccines have suboptimal efficacy and do not provide adequate protection against drifted and shifted strains. Thus, the development of a universal influenza vaccine that induces long-lasing immunity and protects against a broad range of strains is crucial.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001103","type":"journal-article","created":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T09:00:08Z","timestamp":1642323608000},"page":"119-125","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Influenza vaccines: where we are, where we are going"],"prefix":"10.1097","volume":"34","author":[{"given":"Nadim","family":"Khalil","sequence":"first","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA"},{"name":"Division of Infectious Diseases, Department Pediatrics, London Health Sciences Centre, London, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David I.","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7005a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2021\u201322 influenza season","volume":"70","author":"Grohskopf","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"e2021053745","DOI":"10.1542\/peds.2021-053745","article-title":"Recommendations for prevention and control of influenza in children, 2021\u20132022","volume":"148","year":"2021","journal-title":"Pediatrics"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.15585\/mmwr.mm6937a6","article-title":"Decreased influenza activity during the COVID-19 pandemic \u2013 United States, Australia, Chile, and South Africa, 2020","volume":"69","author":"Olsen","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1016\/j.vaccine.2020.02.049","article-title":"Influenza vaccine effectiveness against influenza-associated hospitalization in children: a systematic review and meta-analysis","volume":"38","author":"Kalligeros","year":"2020","journal-title":"Vaccine"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/cid\/ciab270","article-title":"Effectiveness of influenza vaccination in preventing hospitalization due to influenza in children: a systematic review and meta-analysis","volume":"73","author":"Boddington","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"e2020019901","DOI":"10.1542\/peds.2020-019901","article-title":"Antibody response and protection after receipt of inactivated influenza vaccine: a systematic review","volume":"147","author":"Wall","year":"2021","journal-title":"Pediatrics"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10995-019-02844-y","article-title":"Influenza vaccine efficacy and effectiveness in pregnant women: systematic review and meta-analysis","volume":"24","author":"Quach","year":"2020","journal-title":"Matern Child Health J"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.vaccine.2019.12.056","article-title":"The effectiveness of influenza vaccination in pregnancy in relation to child health outcomes: systematic review and meta-analysis","volume":"38","author":"Jarvis","year":"2020","journal-title":"Vaccine"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2020.06.071","article-title":"Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III study in healthy population aged \u22653 years","volume":"38","author":"Chu","year":"2020","journal-title":"Vaccine"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1016\/j.vaccine.2020.03.048","article-title":"Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in healthy subjects aged 3 to 17 years old: a phase III, open label, single-arm study","volume":"38","author":"Chang","year":"2020","journal-title":"Vaccine"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1016\/j.vaccine.2020.09.004","article-title":"Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: an updated systematic review and meta-analysis","volume":"39","author":"Lee","year":"2021","journal-title":"Vaccine"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.vaccine.2019.09.105","article-title":"Comparative effectiveness of high dose versus adjuvanted influenza vaccine: a retrospective cohort study","volume":"38","author":"van Aalst","year":"2020","journal-title":"Vaccine"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/cid\/ciaa160","article-title":"Relative and absolute effectiveness of high-dose and standard-dose influenza vaccine against influenza-related hospitalization among older adults \u2013 United States, 2015\u20132017","volume":"72","author":"Doyle","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.vaccine.2021.02.014","article-title":"Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: a randomized controlled phase II dose-finding trial","volume":"39","author":"Chang","year":"2021","journal-title":"Vaccine"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"A15","DOI":"10.1016\/j.vaccine.2020.11.037","article-title":"Influenza vaccination in immunocompromised populations: strategies to improve immunogenicity","volume":"39","author":"Caldera","year":"2021","journal-title":"Vaccine"},{"key":"R21-20250730","first-page":"593","article-title":"Immunogenicity of high dose influenza vaccine for patients with inflammatory bowel disease on anti-TNF monotherapy: a randomized clinical trial","volume":"26","author":"Caldera","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2665-9913(19)30094-3","article-title":"Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-comparator trial","volume":"2","author":"Colmegna","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.vaccine.2019.10.032","article-title":"Protection provided by influenza vaccine against influenza-related hospitalisation in \u226565 year olds: early experience of introduction of a newly licensed adjuvanted vaccine in England in 2018\/19","volume":"38","author":"Pebody","year":"2020","journal-title":"Vaccine"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3390\/vaccines8030446","article-title":"Evaluating the relative vaccine effectiveness of adjuvanted trivalent influenza vaccine compared to high-dose trivalent and other egg-based influenza vaccines among older adults in the US during the 2017\u20132018 influenza season","volume":"8","author":"Pelton","year":"2020","journal-title":"Vaccines"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/cid\/ciab152","article-title":"Relative effectiveness of adjuvanted trivalent inactivated influenza vaccine versus egg-derived quadrivalent inactivated influenza vaccines and high-dose trivalent influenza vaccine in preventing influenza-related medical encounters in US adults \u226565 years during the 2017\u20132018 and 2018\u20132019 influenza seasons","volume":"73","author":"Boikos","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1016\/j.vaccine.2021.08.021","article-title":"Improved immunologic responses to heterologous influenza strains in children with low preexisting antibody response vaccinated with MF59-adjuvanted influenza vaccine","volume":"39","author":"Palladino","year":"2021","journal-title":"Vaccine"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"8224","DOI":"10.1016\/j.vaccine.2020.10.036","article-title":"Repeated exposure to an MF-59 adjuvanted quadrivalent subunit influenza vaccine (aQIV) in children: results of two revaccination studies","volume":"38","author":"Vesikari","year":"2020","journal-title":"Vaccine"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.vaccine.2020.11.051","article-title":"Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older","volume":"39","author":"Winokur","year":"2021","journal-title":"Vaccine"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1086\/656583","article-title":"Cell culture\u2013derived influenza vaccines: has their time come?","volume":"51","author":"Bernstein","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"e692","DOI":"10.1093\/cid\/ciaa1944","article-title":"Relative effectiveness of the cell-derived inactivated quadrivalent influenza vaccine versus egg-derived inactivated quadrivalent influenza vaccines in preventing influenza-related medical encounters during the 2018\u20132019 influenza season in the United States","volume":"73","author":"Boikos","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"e665","DOI":"10.1093\/cid\/ciaa371","article-title":"Relative effectiveness of the cell-cultured quadrivalent influenza vaccine compared to standard, egg-derived quadrivalent influenza vaccines in preventing influenza-like illness in 2017\u20132018","volume":"71","author":"Boikos","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R32-20250730","doi-asserted-by":"crossref","first-page":"6334","DOI":"10.1016\/j.vaccine.2020.07.023","article-title":"A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017\u201318 influenza season","volume":"38","author":"Divino","year":"2020","journal-title":"Vaccine"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1016\/j.vaccine.2020.06.023","article-title":"A randomized controlled trial of antibody response to 2018\u201319 cell-based vs. egg-based quadrivalent inactivated influenza vaccine in children","volume":"38","author":"Moehling","year":"2020","journal-title":"Vaccine"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1093\/cid\/ciab566","article-title":"Comparison of the immunogenicity of cell culture-based and recombinant quadrivalent influenza vaccines to conventional egg-based quadrivalent influenza vaccines among healthcare personnel aged 18\u201364 years: a randomized open-label trial","volume":"73","author":"Dawood","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJMoa065368","article-title":"Live attenuated versus inactivated influenza vaccine in infants and young children","volume":"356","author":"Belshe","year":"2007","journal-title":"N Engl J Med"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1001\/jama.2009.265","article-title":"Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel","volume":"301","author":"Wang","year":"2009","journal-title":"JAMA"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jaci.2019.12.010","article-title":"Safety of live attenuated influenza vaccine (LAIV) in children with moderate to severe asthma","volume":"145","author":"Turner","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R38-20250730","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/14760584.2021.1925113","article-title":"Safety of live attenuated influenza vaccine (LAIV) in children and adults with asthma: a systematic literature review and narrative synthesis","volume":"20","author":"Bandell","year":"2021","journal-title":"Expert Rev Vaccines"},{"issue":"(Suppl_4)","key":"R39-20250730","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1093\/infdis\/jiab269","article-title":"Influenza vaccines: successes and continuing challenges","volume":"224","author":"Becker","year":"2021","journal-title":"J Infect Dis"},{"key":"R40-20250730","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1016\/j.vaccine.2021.05.011","article-title":"Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research","volume":"39","author":"Ferdinands","year":"2021","journal-title":"Vaccine"},{"key":"R41-20250730","article-title":"Vaccine effectiveness against acute respiratory illness hospitalizations for influenza-associated pneumonia during the 2015\u20132016 to 2017\u20132018 seasons, US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN)","author":"Ghamande","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R42-20250730","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S1473-3099(19)30393-7","article-title":"Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial","volume":"20","author":"Bernstein","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"R43-20250730","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","article-title":"A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial","volume":"27","author":"Nachbagauer","year":"2021","journal-title":"Nat Med"},{"key":"R44-20250730","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/vaccines8030389","article-title":"A vaccine displaying a trimeric influenza-A HA stem protein on capsid-like particles elicits potent and long-lasting protection in mice","volume":"8","author":"Thrane","year":"2020","journal-title":"Vaccines"},{"key":"R45-20250730","doi-asserted-by":"crossref","first-page":"5987","DOI":"10.1016\/j.vaccine.2020.07.015","article-title":"A biomimetic VLP influenza vaccine with interior NP\/exterior M2e antigens constructed through a temperature shift-based encapsulation strategy","volume":"38","author":"Wei","year":"2020","journal-title":"Vaccine"},{"key":"R46-20250730","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3390\/v13091708","article-title":"Influenza antigens NP and M2 confer cross protection to BALB\/c mice against lethal challenge with H1N1, pandemic H1N1 or H5N1 influenza A viruses","volume":"13","author":"Mytle","year":"2021","journal-title":"Viruses"},{"key":"R47-20250730","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/infdis\/jiz593","article-title":"Modified vaccinia ankara\u2013vectored vaccine expressing nucleoprotein and matrix protein 1 (M1) activates mucosal M1-specific T-cell immunity and tissue-resident memory T cells in human nasopharynx-associated lymphoid tissue","volume":"222","author":"Puksuriwong","year":"2020","journal-title":"J Infect Dis"},{"key":"R48-20250730","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1016\/j.vaccine.2021.06.072","article-title":"Universal influenza vaccine based on conserved antigens provides long-term durability of immune responses and durable broad protection against diverse challenge virus strains in mice","volume":"39","author":"Lo","year":"2021","journal-title":"Vaccine"},{"key":"R49-20250730","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3390\/v13071280","article-title":"Universal live-attenuated influenza vaccine candidates expressing multiple M2e epitopes protect ferrets against a high-dose heterologous virus challenge","volume":"13","author":"Mezhenskaya","year":"2021","journal-title":"Viruses"},{"key":"R50-20250730","article-title":"Single replication M2SR influenza vaccine induced immune responses associated with protection against human challenge with highly drifted H3N2 influenza strain","author":"Eiden","year":"2021","journal-title":"J Infect Dis"},{"key":"R51-20250730","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(20)32014-6","article-title":"Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18\u201364 years) and older adults (\u226565 years): two multicentre, randomised phase 3 trials","volume":"396","author":"Ward","year":"2020","journal-title":"Lancet"},{"key":"R52-20250730","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/s41467-021-21508-6","article-title":"Epigraph hemagglutinin vaccine induces broad cross-reactive immunity against swine H3 influenza virus","volume":"12","author":"Bullard","year":"2021","journal-title":"Nat Commun"},{"key":"R53-20250730","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1473-3099(19)30584-5","article-title":"Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study","volume":"20","author":"Liebowitz","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"R54-20250730","doi-asserted-by":"crossref","first-page":"e2035693","DOI":"10.1001\/jamanetworkopen.2020.35693","article-title":"Immunogenicity and safety of reduced-dose intradermal vs intramuscular influenza vaccines: a systematic review and meta-analysis","volume":"4","author":"Egunsola","year":"2021","journal-title":"JAMA Network Open"},{"key":"R55-20250730","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.1016\/j.vaccine.2020.07.064","article-title":"Acceptability of an inactivated influenza vaccine delivered by microneedle patch: results from a phase I clinical trial of safety, reactogenicity, and immunogenicity","volume":"38","author":"Frew","year":"2020","journal-title":"Vaccine"},{"key":"R56-20250730","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/pharmaceutics13010068","article-title":"Promising adjuvants and platforms for influenza vaccine development","volume":"13","author":"Zhu","year":"2021","journal-title":"Pharmaceutics"},{"key":"R57-20250730","first-page":"73","article-title":"Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial","volume":"21","author":"Shinde","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R58-20250730","doi-asserted-by":"crossref","first-page":"e4278","DOI":"10.1093\/cid\/ciaa1673","article-title":"Induction of cross-reactive hemagglutination inhibiting antibody and polyfunctional CD4+ T-cell responses by a recombinant Matrix-M\u2013adjuvanted hemagglutinin nanoparticle influenza vaccine","volume":"73","author":"Shinde","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R59-20250730","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1097\/INF.0000000000003247","article-title":"Immunogenicity and safety of AS03-adjuvanted H5N1 influenza vaccine in children 6\u201335 months of age: results from a phase 2, randomized, observer-blind, multicenter, dose-ranging study","volume":"40","author":"Kim","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"R60-20250730","doi-asserted-by":"crossref","first-page":"17957","DOI":"10.1073\/pnas.1906613117","article-title":"Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans","volume":"117","author":"Ellebedy","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R61-20250730","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/irv.12780","article-title":"Nonneutralizing antibody responses following A (H1N1) pdm09 influenza vaccination with or without AS03 adjuvant system","volume":"15","author":"Friel","year":"2021","journal-title":"Influenza Other Respir Viruses"},{"key":"R62-20250730","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/irv.12755","article-title":"Clinical phase II and III studies of an AS03-adjuvanted H5N1 influenza vaccine produced in an EB66\u00ae cell culture platform","volume":"14","author":"Endo","year":"2020","journal-title":"Influenza Other Respir Viruses"},{"key":"R63-20250730","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1016\/j.vaccine.2020.07.022","article-title":"Inactivated influenza vaccine formulated with single-stranded RNA-based adjuvant confers mucosal immunity and cross-protection against influenza virus infection","volume":"38","author":"Kim","year":"2020","journal-title":"Vaccine"},{"key":"R64-20250730","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-91445-3","article-title":"Effective inactivated influenza vaccine for the elderly using a single-stranded RNA-based adjuvant","volume":"11","author":"Bang","year":"2021","journal-title":"Sci Rep"},{"key":"R65-20250730","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3390\/vaccines8040754","article-title":"Repurposing of miltefosine as an adjuvant for influenza vaccine","volume":"8","author":"Lu","year":"2020","journal-title":"Vaccines"},{"key":"R66-20250730","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(15)00354-0","article-title":"Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous nonvaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b\/3 trial","volume":"16","author":"Hung","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R67-20250730","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiab206","article-title":"Topical imiquimod does not provide an adjuvant effect when administered with inactivated influenza A\/H5N1 vaccine in healthy young adults","author":"El Sahly","year":"2021","journal-title":"J Infect Dis"},{"key":"R68-20250730","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jinf.2021.07.010","article-title":"Seasonal trivalent inactivated influenza vaccine with topical imiquimod in immunocompromised patients: a randomized controlled trial","volume":"83","author":"Mombelli","year":"2021","journal-title":"J Infect"},{"key":"R69-20250730","first-page":"3771","article-title":"Polymeric pathogen-like particles-based combination adjuvants elicit potent mucosal T cell immunity to influenza A virus","volume":"11","author":"Kingstad-Bakke","year":"2020","journal-title":"Front Immunol"},{"key":"R70-20250730","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1016\/j.vaccine.2020.09.062","article-title":"Protective efficacy of a polyvalent influenza A DNA vaccine against both homologous (H1N1pdm09) and heterologous (H5N1) challenge in the ferret model","volume":"39","author":"Guilfoyle","year":"2021","journal-title":"Vaccine"},{"key":"R71-20250730","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3390\/vaccines8030448","article-title":"Immunogenicity and protective efficacy of influenza a DNA vaccines encoding artificial antigens based on conservative hemagglutinin stem region and M2 protein in mice","volume":"8","author":"Bazhan","year":"2020","journal-title":"Vaccines"},{"key":"R72-20250730","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1038\/s41598-020-60783-z","article-title":"Immunization with DNA prime-subunit protein boost strategy based on influenza H9N2 virus conserved matrix protein M1 and its epitope screening","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"key":"R73-20250730","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1473-3099(11)70240-7","article-title":"DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials","volume":"11","author":"Ledgerwood","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R74-20250730","doi-asserted-by":"crossref","first-page":"e0206837","DOI":"10.1371\/journal.pone.0206837","article-title":"DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: a phase 1 randomized clinical trial","volume":"13","author":"Houser","year":"2018","journal-title":"PLoS One"},{"key":"R76-20250730","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"R77-20250730","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","article-title":"A multitargeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice","volume":"28","author":"Freyn","year":"2020","journal-title":"Mol Ther"},{"key":"R78-20250730","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/vaccines8010123","article-title":"mRNA vaccines encoding the HA protein of influenza A H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice","volume":"8","author":"Zhuang","year":"2020","journal-title":"Vaccines"},{"key":"R79-20250730","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:10:27Z","timestamp":1753899027000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001103","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]}}}